Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today?InvestorPlace • 03/11/22
MarketWatch: U.S.-listed China stocks sink as jitters build about overseas listingsMarket Watch • 03/10/22
These Chinese stocks are down sharply on Thursday. Here's what could be behind the declineCNBC • 03/10/22
Zai Lab Limited (ZLAB) CEO Samantha Du on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Zai Lab Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2021GlobeNewsWire • 03/01/22
Zai Lab Announces Breakthrough Therapy Designation Granted for Repotrectinib in ChinaGlobeNewsWire • 02/17/22
Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic CancerGlobeNewsWire • 01/12/22
Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPAGlobeNewsWire • 01/06/22
Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious DiseasesGlobeNewsWire • 12/22/21
Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia GravisGlobeNewsWire • 12/17/21
China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)GlobeNewsWire • 12/16/21
Here are the 10 U.S.-listed Chinese stocks with the greatest American ownership — and Alibaba's not one of themCNBC • 12/14/21
Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China's National Reimbursement Drug List for First-Line Ovarian CancerGlobeNewsWire • 12/03/21
Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian CancerGlobeNewsWire • 11/30/21